Small cell lung cancer (SCLC) is an aggressive form of lung cancer characterized by dismal
prognosis. Although SCLC may initially respond well to platinum-based chemotherapy, it …

Small cell lung cancer (SCLC) is a type of neuroendocrine tumor with high malignancy and
poor prognosis. Besides the de novo SCLC, there is transformed SCLC, which has similar …

Transcription factors (TFs) are indispensable for the modulation of various signaling
pathways associated with normal cell homeostasis and disease conditions. Among cancer …

Lung cancer (LC) is a heterogeneous disease consisting mainly of two subtypes, non-small
cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and remains the leading …

Small cell lung cancer (SCLC), accounting for around 13% of all lung cancers, often results
in rapid tumor growth, early metastasis, and acquired therapeutic resistance. The POU class …

Small cell lung cancer (SCLC) arises in peribronchial locations and infiltrates the bronchial
submucosa, including about 15% of lung cancer cases. Despite decades of research, the …

Small-cell lung cancer (SCLC) is a devastating subtype of lung cancer with few therapeutic
options. Despite the advent of immunotherapy, platinum-based chemotherapy is still the …

Small cell lung cancer (SCLC) is a recalcitrant, relatively immune-cold, and deadly subtype
of lung cancer. SCLC has been viewed as a single or homogenous disease that includes …

Background Small cell lung cancer (SCLC) is an aggressive lung cancer subtype that is
associated with high recurrence and poor prognosis. Due to lack of potential drug targets …

Small cell lung cancer (SCLC) is an aggressive disease, with patients diagnosed with either
early-stage, limited stage, or extensive stage of SCLC tumor progression. Discovering and …